Champions ImmunoGraft™ Platform

The Champions ImmunoGraft platform combines Champions TumorGraft® patient-derived xenograft (PDX) models and humanized immune system mice, created by inoculating human hematopoetic cells into immunodeficient mice.

The result in an innovative tool for evaluating efficacy and mechanisms of action of a variety of cancer therapeutics that modulate human immunity, such as checkpoint inhibitors, monoclonal antibodies, therapeutic cancer vaccines, and cytokine-based therapies. Learn more.